OBI announces the termination of OBI-3424 Phase II trial

Following a strategic portfolio review, the Board of Directors of OBI Pharma, Inc. (4174) has decided to terminate the OBI-3424-001 trial today (March 11, 2024), while continuing the collaboration of OBI-3424 with partners, given that the OBI-3424 development is still ongoing. Dr. Heidi Wang, the Chief Executive Officer of OBI Pharma, emphasized that this decision […]